{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T16:11:39Z","timestamp":1785427899851,"version":"3.56.0"},"reference-count":10,"publisher":"American Association for Cancer Research (AACR)","issue":"3","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Although endocrine prevention has proven to be successful in reducing estrogen receptor (ER)\u2013positive breast cancer, there is still no pharmacologic strategy for preventing ER-negative and BRCA1-associated disease. The study by Moyer and colleagues demonstrated that RXR agonists, particularly IRX4204, delay tumor onset in BRCA1-deficient and triple-negative mouse models, suggesting a potential preventive role through immunomodulation. Yet the translational road ahead is complex, limited by biological uncertainty, sociocultural barriers, and safety concerns. A rational next step may be to carefully design window-of-opportunity trials in BRCA1 carriers undergoing risk-reducing bilateral mastectomy to assess biomarker modulation and tolerability.<\/jats:p>\n                  <jats:p>See related article by Moyer et al., p. 161<\/jats:p>","DOI":"10.1158\/1940-6207.capr-25-0481","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T08:09:26Z","timestamp":1772525366000},"page":"133-135","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Long and Winding Road toward Prevention of Estrogen Receptor\u2013Negative and BRCA1-Associated Breast Cancer"],"prefix":"10.1158","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2635-4491","authenticated-orcid":false,"given":"Andrea","family":"DeCensi","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03g001n57","id-type":"ROR","asserted-by":"publisher"}],"name":"Champalimaud Foundation 1 Breast Department, Clinical Cancer Center, , Lisbon, Portugal."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1797-5296","authenticated-orcid":false,"given":"Matteo","family":"Lambertini","sequence":"additional","affiliation":[{"name":"2Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genoa, Italy."},{"name":"3Department of Medical Oncology, IRCCS Azienda Ospedaliera Metropolitana, Genoa, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,3,3]]},"reference":[{"key":"2026030303092043400_bib1","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","article-title":"Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study","volume":"90","author":"Fisher","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"2026030303092043400_bib2","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0140-6736(13)62292-8","article-title":"Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial","volume":"383","author":"Cuzick","year":"2014","journal-title":"Lancet"},{"key":"2026030303092043400_bib3","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1056\/NEJMoa1103507","article-title":"Exemestane for breast-cancer prevention in postmenopausal women","volume":"364","author":"Goss","year":"2011","journal-title":"N Engl J Med"},{"key":"2026030303092043400_bib4","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1200\/JCO.18.01779","article-title":"Randomized placebo controlled trial of low-dose tamoxifen to prevent local and contralateral recurrence in breast intraepithelial neoplasia","volume":"37","author":"DeCensi","year":"2019","journal-title":"J Clin Oncol"},{"key":"2026030303092043400_bib5","first-page":"161","article-title":"Targeting the RXR pathway for the prevention of triple negative breast cancer","volume":"19","author":"Moyer","year":"2026","journal-title":"Cancer Prev Res (Phila)"},{"key":"2026030303092043400_bib6","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1158\/1940-6207.CAPR-19-0310","article-title":"A randomized, placebo-controlled, double-blind, dose escalation, single dose, and steady-state pharmacokinetic study of 9cUAB30 in healthy volunteers","volume":"12","author":"Kolesar","year":"2019","journal-title":"Cancer Prev Res (Phila)"},{"issue":"Suppl 4","key":"2026030303092043400_bib7","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1200\/jco.2014.32.4_suppl.169","article-title":"An open-label phase II clinical trial of the RXR agonist IRX4204 in taxane-resistant, castration-resistant metastatic prostate cancer (CRPC)","volume":"32","author":"Kabbinavar","year":"2014","journal-title":"J Clin Oncol"},{"key":"2026030303092043400_bib8","first-page":"151","article-title":"Epidemiological characteristics of and risk factors for breast cancer in the world","volume":"11","author":"Momenimovahed","year":"2019","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"2026030303092043400_bib9","doi-asserted-by":"crossref","article-title":"OlympiA: a phase 3, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients w\/ germline BRCA1 & BRCA2 pathogenic variants & highrisk HER2-negative primary breast cancer","author":"Garber","DOI":"10.1158\/1557-3265.SABCS24-GS1-09"},{"key":"2026030303092043400_bib10","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41523-025-00745-8","article-title":"Window-of-opportunity trials to screen effective agents and optimize dose in breast cancer prevention","volume":"11","author":"Aurilio","year":"2025","journal-title":"NPJ Breast Cancer"}],"container-title":["Cancer Prevention Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerpreventionresearch\/article-pdf\/19\/3\/133\/3743486\/capr-25-0481.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerpreventionresearch\/article-pdf\/19\/3\/133\/3743486\/capr-25-0481.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T08:09:28Z","timestamp":1772525368000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerpreventionresearch\/article\/19\/3\/133\/774881\/The-Long-and-Winding-Road-toward-Prevention-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,3]]},"references-count":10,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3,3]]},"published-print":{"date-parts":[[2026,3,3]]}},"URL":"https:\/\/doi.org\/10.1158\/1940-6207.capr-25-0481","relation":{},"ISSN":["1940-6207","1940-6215"],"issn-type":[{"value":"1940-6207","type":"print"},{"value":"1940-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,3]]}}}